Literature DB >> 15097037

Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma.

Masatoshi Akamatsu1, Haruhiko Yoshida, Shuichiro Shiina, Takuma Teratani, Ryosuke Tateishi, Shuntaro Obi, Shinpei Sato, Yukihiro Koike, Tomonori Fujishima, Takashi Ishikawa, Yasushi Shiratori, Masao Omata.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) genotype and virus load, the strongest determinants of the efficacy of interferon therapy, have been presumed to be associated with risk for hepatocellular carcinoma (HCC). This study was conducted to elucidate whether these two factors are capable of predicting the prognosis of patients with HCC.
METHODS: A total of 371 patients with HCV infection (258 men and 113 women; median age, 66 years; range, 37-88 years) who developed HCC between January 1993 and December 1999 were enrolled. Overall survival and recurrence-free survival were analysed with the Cox proportional hazard regression according to HCV genotype (type 1 versus type 2) and virus load (above versus below 100 kIU/ml).
RESULTS: Of the 371 patients, 346 received locoregional treatments (ethanol injection, microwave, radiofrequency, or surgery), and 307 achieved complete response as determined by subsequent imaging studies. The remaining 25 patients underwent arterial embolization or chemotherapy. Cox proportional hazard regression showed that neither genotype (P = 0.814) nor virus load (P = 0.958) were significant predictors for survival (P = 0.814 and 0.958, respectively) and recurrence (P = 0.505 and 0.736, respectively).
CONCLUSIONS: Neither genotype nor virus load of HCV affected prognosis of HCC patients.

Entities:  

Mesh:

Year:  2004        PMID: 15097037     DOI: 10.1097/00042737-200405000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus.

Authors:  Junichi Shindoh; Kiyoshi Hasegawa; Nobuyuki Takemura; Kiyohiko Omichi; Takeaki Ishizawa; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

2.  Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study.

Authors:  Yang Luo; Yue Zhang; Di Wang; Di Shen; Yi-Qun Che
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

3.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

4.  Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma.

Authors:  Hye Kyong Park; Sang Soo Lee; Chang Bin Im; Changjo Im; Ra Ri Cha; Wan Soo Kim; Hyun Chin Cho; Jae Min Lee; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok-Jae Lee
Journal:  BMC Cancer       Date:  2019-08-20       Impact factor: 4.430

Review 5.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.